[Roxithromycin (RU 28965), a new macrolide effective against pulmonary infections].
Roxithromycin, a new macrolide, has favorable pharmacological properties: it is acid stable and well absorbed, and its prolonged half-life allows b.i.d. prescription of 150 mg. In our open prospective study we found an etiologic infectious agent in 16 (80%) of 20 patients presenting with "atypical" pneumonia. Ten of the 16 pneumonias were due to an organism sensitive to roxithromycin (gram+ cocci, gram- rods, mycoplasma and chlamydia), and 6 to a virus. Therapeutic success was obtained in greater than or equal to 90%. The treatment was well tolerated with fewer gastrointestinal disorders than with erythromycin.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007933:Leucomycins / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy*; D011024:Pneumonia, Viral / Q000188:drug therapy*
D007933:Leucomycins
Roxithromycine (RU 28965), un nouveau macrolide efficace dans les infections pulmonaires.